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Abstract 
 
Spatial gene expression analysis platforms have been widely used for a variety of applications 
ranging from pathogen detection to the analysis of spatial variation of an mRNA in a tissue section. 
Traditionally, this is accomplished by using in situ polymerase chain reaction (in situ PCR) or in 
situ hybridization (ISH). In addition, laser capture microdissection (LCM) followed by RT-qPCR 
of the locally captured tissue has also been used to study these spatial variations at a molecular 
level. But, all of the above techniques are plagued with different issues such as low sensitivity in 
the case of ISH, low reproducibility and long experimental run time for in situ PCR, and long 
sample acquisition and purification times for the LCM based techniques. This calls for a method 
that can reliably, rapidly and with high sensitivity perform spatial gene expression analysis starting 
from a tissue sample. We present a novel approach that combine microfabrication techniques with 
reverse transcription-loop mediated isothermal amplification (RT-LAMP) to achieve this goal. 
This novel technique uses a micro-fabricated chip with an array of micro-wells with knife-like 
sharp well edges to assist in division of a tissue cryosection into small pieces in a process we call 
“tissue pixelation”. The array consists of over five thousand 100um (side length) pyramidal wells 
with a volume of ~ 175pL each. Following the above tissue transfer step, reagents are loaded onto 
the chip into the individual wells using a parallel loading process and independent picoliter volume 
RT-LAMP reactions are performed in each well. Towards this end, we have completed and 
characterized the chip fabrication, tissue pixelation and picoliter volume reagent loading on chip 
steps. In addition to this, we have also designed and characterized a novel RT-LAMP reaction for 
topoisomerase II alpha (TOP2A) mRNA biomarker for LNCaP prostate cancer cells. 
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1 Introduction 
 
1.1 The role of gene expression analysis 
Gene expression analysis can be simply described as the study of gene products i.e. functional 
RNA or protein products by using techniques such as imaging, amplification, probe hybridization 
or sequencing-based detection methods. This study of gene regulation provides insights into 
normal cellular processes such as differentiation and also into abnormal or pathological processes. 
For the remainder of the discussion, we will focus on the use of gene expression analysis for 
pathological processes.  
In depth molecular understanding of diseases such as cancer can greatly affect their timely 
diagnosis and correct prognosis [1]. Take prostate cancer for example - early stages of this disease 
are confined to the organ and generally curable by radiation therapy or surgery if detected in time. 
Elevated levels of prostate specific antigen 2 (PSA) has been widely used as a screening test for 
prostate cancer and is considered one of the best prostate cancer biomarkers[2], [3]. But, it was 
found that men with obstructive or inflammatory uropathies also show elevated PSA levels (4-
10ng/ml)[4] , and this lowered the specificity of PSA as a biomarker. In this scenario, a molecular 
understanding of prostate cancer development and progression would help identify additional 
biomarkers with increased specificity and aid the discovery of new tumor-specific therapeutic 
targets. This is where gene expression analysis plays a vital role. Genome-wide studies of bulk 
tumors provide quantitative gene expression data on the tumor as a whole.[5] These techniques 
such as cDNA microarrays and serial analysis of gene expression can perform transcript level 
analysis of thousands of genes in a single experiment and isolate genes that are overexpressed in 
tumor tissues compared to the healthy ones[6]–[9]. These can then serve as prospective markers 
for disease diagnosis, monitoring and treatment but further characterizations of each of these 
would be needed before they can be used in a clinical setting.  
1.2 Need for a spatially mapped gene expression analysis 
Spatially mapped gene expression analysis refers to localizing mRNA expression to its original 
tissue location. Adding the spatial information about the expressed mRNA could be of significance 
for a variety of applications which are discussed below:  
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1.2.1 Cancer biomarker characterization and Intra-tumor heterogeneity analysis 
Biomarkers can generally by classified into 2 broad categories based on their application. 
The first category of biomarkers referred to as prognostic, predictive, and risk biomarkers, 
are measured before therapy and are used for disease characterization. The second category 
of biomarkers are used for measuring the response to the therapy. Existing therapies of 
cancers such as prostate cancer, target and eradicate the bulk of cells within a tumor but 
most patients go on to develop androgen-independent disease that remains incurable by 
current treatment strategies.[10] This can be explained by the presence of cellular 
differences within a single tumor usually referred to as Tumor heterogeneity. More 
specifically, tumor heterogeneity refers to the presence of distinctly different 
subpopulations within a tumor capable of breeding true.[11]  These subpopulations differ 
in characteristics such as cellular morphology, tumor histology, receptors, enzymes, 
tumorigenicity, resistance to treatment, metastatic ability and cytogenetic markers, among 
others[12]–[16]. The failure of the current cancer treatment strategies can be attributed to 
the fact the cancer treatment drugs usually target only a subpopulation of tumor cells which 
are sensitive to it while the remainder of the cancer remains unaffected[11]. To characterize 
and analyze this tumor heterogeneity, a spatially mapped gene expression analysis is 
required as the bulk analysis techniques would average out these intra-tumor cellular 
differences. Assessing the effect of these drugs on different tumor subpopulations and 
modifying the treatment strategy accordingly would require the use of such spatial gene 
expression analysis platforms.  
 
The role of spatial gene expression analysis platforms becomes even more pronounced if 
we look at the clinical workflow for cancer diagnosis and prognosis. In the current clinical 
setting, cancer diagnosis is usually done on biopsies of a small region of a tumor and due 
to intra-tumor heterogeneity this may not provide representative biological information for 
the tumor as a whole. This is shown in the figure 1.1. Also, since biomarker that reveal 
disease mechanisms are often therapeutic targets and used for both, the selection of patients 
who could benefit from a therapy and monitoring response to the treatment, intra-tumor 
heterogeneity for expression of these biomarkers could significantly affect the 
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effectiveness of targeted therapies. [1]. In essence, every time a patient is biopsied after 
such targeted therapy, they could be sampling different cell subpopulations with different 
original expression levels of the biomarker and thus there would be no reference to 
compare the progress. This problem can be solved if the biomarker of interest has been 
shown to have spatial homogeneity and robust expression during disease progression, 
which are the important characteristics of any good predictive biomarker[1]. This 
characterization would require a quantitative/semi quantitative spatial gene expression 
analysis platform to visualize the spatial variance of the biomarker.  
 
This spatial gene expression analysis study can be done on an mRNA level or a protein 
level. On a protein level, immunodetection techniques such as immunohistochemistry 
(IHC) and immunofluorescence (IF) allow rapid evaluation of antigenic markers in tissue 
sections and provide semi-quantitative analysis of the expression of proteins on interest. 
For example, expression analysis of HER2 and hormone receptors using IHC is routinely 
used for breast cancer diagnosis and guiding the treatment decisions[1]. But, since 
monoclonal antibodies for all such antigen biomarkers are not available [17], mRNA 
analysis for such antigens is done using various techniques discussed in the next section. 
Not only that, mRNA analysis adds another level of information about the biomarker of 
interest which can be useful in making better diagnostic and prognostic decisions. 
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Figure 1.1: Figure showing the effects of intratumor heterogeneity on the predictive value of biomarkers. 
Cancer diagnosis is based on core biopsies which may not be representative of all sub-clones (represented 
by different colored cells). The analysis on such biopsies guide treatment decisions. The treatment 
eliminates the dominant clones if successful, but then the clones resistant to the therapy (yellow) become 
dominant and drive the disease progression. Moreover, distant metastases may arise from cells disseminated 
early during tumor development and the clonal composition of metastatic tumors can be significantly 
different from their primary counterparts. Thus, treatments designed according to initial diagnostic samples 
would yield suboptimal results for metastatic disease[1].  
 
1.2.2 Detecting tumor margins 
When a cancer surgeon is resecting a tumor, identifying the margins between healthy and 
malignant tissue can be a significant challenge. It is crucial to remove every bit of the malignant 
tissue during the surgery as if some portion is missed, it will cause recurrence of the disease. The 
current intraoperative procedure for confirming these margins involves taking out sample(s) from 
the patient and sending it to a pathologist. The pathologist freezes, sections, stains, observes the 
tissue sample under a microscope and gives his judgement about the margin to the surgeon. All of 
this is done while the patient is lying open on the surgery table. In cases where the margins are not 
clear to the pathologist, a second surgery has to be performed after confirmatory immunostaining 
and RT-qPCR analysis of the tissue samples obtained during the first surgery. A schematic of the 
process is shown in the figure 1.2.  As mentioned in the previous section, immunostaining is a 
5 
 
spatial gene expression analysis platform, which in this particular scenario is used to identify the 
margin based on differential expression levels of protein biomarkers. 
 
Figure 1.2: Schematic for current tumor margin detection protocol  
 
 
1.2.3 Detecting pathogens in a tissue sample 
Another major application of spatial gene expression analysis platforms could be identifying 
foreign or pathogenic nucleic acid sequences or proteins in a tissue sample. This application is 
usually seen for in situ PCR techniques where viral RNA or DNA is detected from tissue sections. 
 
 
Figure 1.3: Figure showing the in situ PCR based detection of human herpesvirus type 8 (HHV8) DNA in 
the sperms of a HIV-1 infected man. HHV8 virions in the head of the sperm can be seen as red signals 
following peroxidase-based colorimetric probe detection[18]. 
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1.3 Our technique 
Our technique can perform spatial gene expression analysis at mRNA level semi-quantitatively for 
a particular biomarker. Starting with a tissue cryosection, performing minimal sample preparation 
steps and using real time reverse transcription – loop mediated isothermal amplification (RT-
LAMP) reaction, we can semi-quantitatively assess the abundance and spatial distribution of a 
particular mRNA across the whole tissue section. This technique can be used for all of the above 
applications discussed in the previous sections: Cancer biomarker characterization an intratumor 
heterogeneity analysis, tumor margin detection, and detecting pathogenic nucleic acid sequences 
in a tissue section. A comparative schematic of our technique with the current protocol for tumor 
margin detection is shown in the figure 1.4 and a similar workflow can be visualized for the other 
applications mentioned above. 
 
Figure 1.4: Schematic for tumor margin detection protocol using our technique 
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2 Literature review: 
In this section we will talk about various spatial gene expression analysis techniques that operate 
on an mRNA level, details about the RT-LAMP reaction and rationale for choosing it for our study, 
and our study model. 
 
2.1 mRNA analysis strategies that conserve spatial location: 
 
2.1.1 In-situ RT-PCR:  
In situ RT-PCR uses the same amplification reaction used in Reverse transcription- PCR 
(RT-PCR), but it does that without purifying the total RNA form the starting sample which 
can be tissue or cells. Using this technique the target mRNA of interest can be amplified in 
a fixed cell such that the cell mimics a micro-vessel for the amplification reaction and the 
amplicons can be detected inside its various subcompartments.[18] The protocol involves 
fixing the cells so that the subcellular components are not destroyed during the subsequent 
amplification, followed by a controlled proteinase K digestion step to allow the access of 
amplification reagents to the mRNA template.[18]  Protease digestion is usually followed 
by DNase digestion and, then, by the target specific synthesis of a cDNA molecule using 
the RT enzyme. A DNase digestion step before the amplification reaction prevents the false 
positive signals from the genomic DNA and this step is usually done over-night. The 
detection of the amplification is performed end-point after the amplification reaction is 
complete. The probes for the end-point amplification detection using microscopy can be 
labelled indirectly using biotin or digoxigenin (dig), or directly using a fluorescent label. 
Biotin or dig labelled probes can be detected using enzyme based color detection systems. 
[18] The use of fluorescently labelled nucleotides as shown in “direct in situ PCR” 
protocols leads to false positives because of non-specific incorporation of nucleotides 
during DNA repair by DNA polymerase.[19]–[21] A brief description of the protocol can 
be seen in figure 2.1. 
 
Theoretically, the applications of this technique are abundant. It can be used to assist in the 
determination of the number of cells infected with a specific virus[22], or the percentage 
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of cells with tumor genes before or after therapy[23]–[28]. But, like any other technique, 
in situ RT-PCR also has its drawbacks and limitations. Since the technique uses end-point 
detection, it can only be used to indicate the presence or absence of a particular RNA at a 
particular sample location and no form of quantitation is possible [19].  Moreover, the 
technique is generally too variable to consistently amplify desired targets within a complex 
tissue matrix [29]–[32].  
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         Figure 2.1: Figuring showing the schematic for in situ PCR/RT-PCR protocol[18] 
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2.1.2 mRNA In Situ Hybridization (mRNA ISH): 
In-situ hybridization is a technique for gene expression analysis where the labelled 
complementary DNA or RNA probes are specifically annealed to the target sequence at its 
native location in fixed tissues or cells. This annealing is followed by visualization of the 
probe location under a microscope[33]. Both RNA and DNA can be used as probes and 
can be labelled with radioactive isotopes, enzymes and fluorochromes [34]–[37]. 
Conventional FISH has been used to analyze copy number variations of mRNA in cells but 
has been reported to be less accurate due to technical limitations [1]. Improved probes have 
been developed for better quantification of spatial gene expression patterns at single cell 
resolution level[35], [38]. The protocol for this technique is described in the figure 2.2. The 
initial steps of tissue fixation and proteinase K digestion are similar to in situ RT-PCR 
technique. Nevertheless, since this method does not use target amplification, it is not as 
sensitive as in situ RT-PCR and has a lower limit of detection of 10-20 target sequence 
copies per cell[32]. 
        
    Figure 2.2: Schematic showing the overview of mRNA FISH protocol 
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Proteinase 
digestion 
(permeabilization) 
mRNA probe-
target 
denaturation 
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Analysis under 
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2.1.3 Laser Capture Microdissection (LCM) followed by RT-qPCR: 
LCM from stained tissue sections allows isolation of morphologically identified cells for 
gene expression analysis and can help remove the problems of tissue heterogeneity [39], 
[40]. Even individual cells can be precisely picked using this technique for downstream 
analysis [39], [40]. These obtained tissue samples can be used for mRNA isolation followed 
by quantitative RT-PCR to accurately and quantitatively study spatially mapped gene 
expression patterns[41]–[43]. Use of Immunostaining to identify specific cells from frozen 
sections based on their antigen expression followed by LCM has also been reported.[39] 
But, performing a spatial gene expression analysis by mapping the results of LCM followed 
by RT-qPCR to their native tissue location is comprised of a 4 step work flow: LCM, tissue 
homogenization and lysis, RNA isolation and RT-qPCR. This makes the technique too 
labor intensive and time consuming to be applicable as a routine laboratory experiment. 
Figure 2.3 shows one of the strategies of LCM. 
 
Figure 2.3: The figure shows Laser-assisted cell picking technique in frozen tissue after 
immunohistochemical staining. A: Kidney cryosection was stained with the RECA-1 antibody 
(rat pan-endothelial), alkaline phosphatase and monoclonal anti-alkaline phosphatase 
(APAAP) , B: A glomerulum is selected. , C: Removal of the adjacent tissue by the UV-laser 
and reduction of the stained glomerulus to obtain a cell cluster with approximately 20 nuclei. , 
D: The cell cluster is harvested with a needle. [39] 
12 
 
2.1.4 2D-RT-qPCR: 
This is a recent technique developed by Armani et al[44] that performs a spatially mapped 
mRNA analysis on tissue cryosections. The process involves scraping off dried tissue using 
a razor from a glass slide into polypropylene tubes of a 384-well plate. This is followed by 
an on-plate RNA purification step using ChargeSwitch magnetic recovery beads in a well 
volume of 40 μL. The final step involves a one-step RT-qPCR reaction performed in individual 
wells. The process allows a quantitative spatial analysis of mRNA starting from a tissue section 
but suffers from lot of standardization issues like tissue transfer process, multiple manual 
sample handling and pipetting steps and issues related with reliable RNA purification on 
plates. The technique apart from being very cumbersome, also has a very low spatial 
resolution compared to the above mentioned competing techniques. This technique has not 
yet been used by other groups and its repeatability is yet to been shown. 
 
Figure 2.4: Schematic showing the 2D-RT-qPCR method. A: Tissue cryosection transfer onto 
a multi-well plate. B Tissue lysis. C Addition of magnetic capture beads. D Immobilization of 
beads and purification of RNA by washing and DNase treatment. E Amplification of RNA by 
RT-qPCR 
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2.2       Reverse transcription –Loop mediated isothermal amplification (RT-LAMP) 
LAMP is a novel nucleic acid amplification method that was first reported by Notomi et al 
in 2000.[45] It is a one-step amplification reaction that amplifies target nucleic acid 
sequence with high specificity and sensitivity under isothermal conditions and has 
sensitivity comparable to traditional PCR.[46] The LAMP reaction can also be used for 
detection of viral RNA or mRNA by adding heat-stable reverse transcriptase to the 
reaction[46], [47]. This section will discuss the mechanism, primer design and key features 
of RT-LAMP reaction. 
 
This technique relies on auto-cycling strand displacement DNA synthesis that is performed 
by a strand displacement DNA polymerase with high activity and a set of two specially 
designed inner and two outer primers. These sets of primers recognize a total of six distinct 
sequences on the target DNA. At the LAMP reaction temperature (60 − 65 ◦C) double 
stranded DNA is in a ‘dynamic equilibrium’ allowing primers to anneal to the 
complimentary sequence in the target double stranded DNA and thereby triggering the 
polymerase to make initial elongations. Initially, all four primers are used, but later during 
the cycling reaction only the inner primers are used for strand displacement DNA synthesis. 
The inner primers are called the forward inner primer (FIP) and the backward inner primer 
(BIP), respectively, and each contains two distinct sequences corresponding to the sense 
and antisense sequences of the target DNA, one for priming in the first stage and the other 
for self-priming in later stages. During the initial elongation, the polymerase releases a 
single stranded DNA that is then used for further downstream reactions of making loop 
structures. A dumbbell or stem loop structure is formed after 6 such steps of annealing, 
elongation and displacement (Figure 2.5).  
 
 
                                 Figure 2.5: Dumbbell shaped DNA that initiates LAMP  
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This structure is the starting element for isothermal amplification. In the subsequent LAMP 
cycling one inner primer hybridizes to the loop on the aforementioned product and initiates 
the displacement DNA synthesis, yielding the original stem–loop DNA in addition to a 
new stem–loop DNA with a stem twice as long. This cycling reaction continues with 
accumulation of 10^9 copies of target in less than an hour. The reaction will stop when 
concentration of free deoxyribonucleotides (dNTPs) is too low or the buffer capacity is 
reached. As a result of this 20 step process, various sized DNA structures (consisting of 
concatenated inverted repeats of the target sequence) are formed. Because LAMP 
recognizes the target by six distinct sequences initially and by four distinct sequences 
afterwards, it is expected to amplify the target sequence with high selectivity. Furthermore, 
an accelerated LAMP procedure has been developed that employs two additional primers 
(LoopF and LoopB) for enhanced specificity and reaction efficiency [48]. The process 
schematic is shown in detail in figure 2.6.  
 
 
2.2.1 Key features:  
The key features of LAMP reaction are as follows: 
- Isothermal:  LAMP does not require complicated thermal cyclers as the ones used for 
PCR for carrying out reactions.  
- Simple visual assessment of amplification: using turbidity or by addition of fluorescent 
reagents (like SYBR green intercalating dye).   
- Low detection limit: As few as 1 copy per reaction have been detected using LAMP 
assays.  
- High specificity: Because 4 primers which identify 6 regions in the target sequence 
need to anneal to the target DNA (instead of only 2 from PCR) likelihood of nonspecific 
amplification from different strands or primer dimmers is lower.  
- Robustness: It requires minimal sample preparation such as purification steps. LAMP 
reactions have been shown to be specific and perform efficiently in the presence of 
PCR inhibitors like cellular debris, urine, stool etc. 
15 
 
- Assay time: Lamp assays can be give detection results in as little as 10min - 15min. It 
depends on the initial template concentration and using LF / LB loop primers is possible 
to decrease a long detection time.  
- Amplification yield: While PCR yields 10ug/mL of DNA copies, LAMP produces 500 
ug/mL allowing detection through turbidity measurements. Overall LAMP has been 
proposed as an ideal technique for nucleic acid amplification for point-of-care devices 
since it has less demanding equipment and has better sensitivity and specificity over 
PCR and other methods.  
 
Since we plan to do an amplification reaction directly from tissue without any RNA 
purification steps, RT-LAMP was our preferred choice over RT-PCR because of the 
aforementioned reasons. 
 
 
2.3 Model and biomarker selection for study:  
Prostate cancer and TOP2a- 
Apart from being the most common cancer diagnosed in men, prostate cancer is also the 
second leading cause of cancer death in the United States, accounting for more than 25,000 
deaths annually according to 2015 cancer statistics [49]. Despite this impact, the molecular 
mechanisms fueling the prostate cancer pathogenesis remain relatively unknown in 
comparison with other common cancers. It has already been shown that prostate tumors 
are particularly heterogeneous and are comprised of cells with different phenotypic 
characteristics and different proliferative and malignant potentials[2], [10]. This gives rise 
to question about the homogeneity of any predictive biomarkers used for prostate cancer 
diagnosis and treatment monitoring. TOP2A, which stands for topoisomerase II alpha, a 
nuclear enzyme involved in processes such as chromosome condensation and chromatid 
separation, has been shown to be upregulated with increasing Gleason score and with 
hormone insensitivity in prostate carcinoma[50]. This is the reason we chose the 
combination of prostate cancer xenografts grown in mice using LNCaP cell line (human 
cell line- prostate cells derived from metastatic site - left supraclavicular lymph node) and 
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the TOP2A mRNA, to test the efficacy of TOP2A as a predictive biomarker and to show 
that it can be used to distinguish malignant cells from healthy cells at a molecular level. 
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  Figure 2.6: Schematic representation of a LAMP reaction mechanism [45] 
 
18 
 
3 Materials and Methods: 
 
 
3.1 Chip microfabrication  
A silicon oxide on silicon chip with an array of microwells was fabricated using wet 
anisotropic Tetra-methyl-ammonium-hydroxide (TMAH) etch. The goal of the chip with 
the array of wells were twofold: 
 
- Sample division: Partitioning a single tissue cryosection into 5625 small pieces (equal 
to the number of wells in the array), keeping the spatial information intact and making 
sure that each small part of the tissue falls into the corresponding well. To achieve this 
feat, we designed the wells to be closely spaced with pointy edges between any 2 wells 
acting as a knife. 
 
- Reaction vessel: In the last step of the on chip RT-LAMP protocol, each well of the 
array on chip acts as an individual reaction vessel for amplification reaction starting 
with tissue sample.  
 
This section describes the fabrication protocol for the chip and its characteristic 
measurements. Figure 3.1 presents a flow diagram for the fabrication.  Undoped single side 
polished silicon wafers were obtained from University Wafers, South Boston, MA. The 
wafers were piranha cleaned (1:3 H2O2-H2SO4) for 10 minutes and thereafter a 135 nm 
layer of silicon oxide was grown in a furnace (Lindberg/Tempress Model 8500) at 1150 ◦C 
for 60 min using the dry oxidation process. In the next step, adhesion promoter Ap8000 
followed by positive AZ1518 photoresist (AZ Electronic Materials, Branchburg, NJ) was 
spin coated to form a 2um on both the sides of wafer. A pre-exposure soft baked for 3 min 
in a hotplate at 110 ◦C was performed followed by ultraviolet exposure using the EVG 600 
aligner system. A 5” iron oxide dark field mask (figure 3.2) was used for the exposure. The 
photoresist was exposed to a dose of 140mJ in “vacuum + hard” contact mode. Since the 
spacing between any 2 wells in the mask was only 3 um, “vacuum + hard” contact is 
necessary to avoid overexposing and losing this feature. 
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Exposed regions were then removed by developing the wafer in AZ 400k developer (1:4 
dilution in water) (AZ Electronic Materials, Branchburg, NJ) for 1 min. The process was 
eyeballed to prevent over-development and loss of edges. A post-exposure bake at 145 C 
for 3 min is done to improve the adhesion of the photoresist features to the silicon dioxide 
layer. This prevent the BOE in the next step to seep through. Thereafter, silicon oxide 
uncovered by photoresist is etched in 10:1 Buffered oxide etchant (BOE) (VWR, Chicago, 
IL) for 6 min revealing silicon and the remaining photoresist is removed using Remover 
PG (MicroChem, Newton, MA) bath at 60 ◦C for 20 min leaving a silicon oxide mask in 
the polished side of the wafer and a protective oxide layer in the bottom side for following 
anisotropic etch. 
 
Anisotropic etch of silicon in tetramethylammonium hydroxide (TMAH) for 100 mins at 
80 ◦C create inverted square pyramids were RT-LAMP amplification reactions will 
happen. For passivation of the silicon surface post etching, 135 nm of silicon oxide was 
grown for 60 min at 1150 ◦C. Several authors have pointed out the surface adsorption 
properties of bare Silicon surface which adversely affect the amplification reactions on 
chip due to high surface area to volume ratio[52]–[55]. Silicon dioxide layer 100nm thick 
or greater has been shown to prevent this.[56].Finally, the chips were scribed using a 
diamond scribe and SEM and surface profilometer measurements were taken.  
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Figure 3.1: Schematic of the process flow for the microfabrication of chips (adapted from paper) 
[51]. Inverted square pyramids were obtained at the end of anisotropic TMAH etch.  
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                       Figure 3.2: AutoCAD image of the microwell chip photolithography mask 
 
Figure 3.3 a) optical image of the chip, b) SEM image of the wells, c) SEM image of the sharp well 
edge shown as red box in image b, d) surface profilometer measurement of fabricated silicon oxide 
micro wells. 
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3.2 Primer design 
A new RT-LAMP reaction was designed for amplifying the TOP2A mRNA and this 
section describes the process of primer design.  
 
RT-LAMP uses two specially designed inner (FIP and BIP) and two outer (F3 and B3) 
primers. Two loop primers (LF and LB) are usually included in the reaction mix to increase 
sensitivity and accelerate the reaction, giving shorter detection times[48]. There are in 
general 3 strategies for designing primers for Reverse-transcription part of any 
amplification reaction: 
 
Method 1: Oligo(dT)N primers-  These primes anneal to the endogenous poly A tail found 
at the 3’ end of eukaryotic mRNA. It generates a full length cDNA but if the template 
contains oligo(A) stretches, it can lead to mispriming and shorter transcript generation 
 
Method 2: Random hexamer primers- They hybridize to many sites throughout the length 
of the RNA and provide uniform representation of all RNA sequences in mRNA. This 
method can be useful for transcripts with secondary structures but it yields truncated 
cDNA. 
 
Method 3: Sequence specific primers- They are custom made primers that target specific 
mRNA sequence and result in a specific cDNA pool. This leads to increased sensitivity but 
the synthesis is limited to only one gene of interest. They are preferred for one step RT- 
LAMP reactions. 
 
We used the method 3 for our reactions and designed the primers using the PrimerExplorer 
application (http : //primerexplorer.jp/). The sequence for the TOP2A mRNA was obtained 
from the NCBI database, shown in the link below: 
 
http://www.ncbi.nlm.nih.gov/nuccore/NM_001067.3 
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The mRNA sequence by convention is shown by the corresponding cDNA sequence. To 
retrieve the mRNA sequence for any gene, you need to find the refseqRNA tab on the right 
column of the page for the gene of interest and use that to retrieve the corresponding mRNA 
sequence. The sequence can be downloaded as a text file and loaded into the primerexplorer 
software. An image of the software interface is shown in the figure 3.4.  
 
To avoid non-specific amplification from genomic DNA, there are 2 important 
characteristics of the primer design that need to be kept in mind: 
 
1. At least one of the primers should flank an exon-exon bridge. This bridge only forms 
post splicing and is not present in genomic DNA, or, 
2. The primers are designed for exons that span a very long intron in between in the 
genomic DNA. For such cases, stem loop structures won’t form (due to size 
constraint) and thus genomic DNA would not amplify. 
 
Keeping these in mind, the final primers were selected and tested by off-chip reactions in 
the laboratory. A set of 5 primers were ordered and tested for amplification. Finally, the 
best primers were selected based on amplification results conducted in laboratory. Figure 
3.5 shows the specifications of the final primer selected. 
 
In the above figure, the stability of the 3’ end at the region F2, 5’ end at the region F1c, 3’ 
end at the region B2, and the 5’ end at the region B1c need to be checked. As these are the 
starting positions of gene replication by primers, their end stability is important. ΔG lower 
or equal to -4.0 kcal/mol for the above mentioned locations is considered acceptable. The 
more negative the ΔG value the better. This can be one of the criteria for selecting the best 
primer set. 
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             Figure 3.4: Primerexplorer LAMP primer design software interface with explanations of options 
 
 
                   Figure 3.5: Specifications of the final primer set selected 
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3.3 Off chip reactions:  
3.3.1 Sample 
1. Purified total RNA:  
- Total RNA was purified from tissue cryosections made using Leica cryostat from 
prostate cancer xenografts grown in mice (LNCaP cells). The Qiagen RNeasy mini kit 
was used and the manufacturer’s protocol was followed for the extraction.  
- Total RNA was also purified from cultured LNCaP cells using the same kit as above.  
 
2. Cells spiked directly in reaction: Cultured LNCaP cells were suspended in DEPC treated 
water in known concentrations after counting using a hemocytometer. This solution in 
varying cell concentrations were used in the reaction.  
3.3.2 RT-LAMP 
Reaction components: 
The RT-LAMP assay previously shown by our lab to work with HIV-1 rna and whole 
blood was adapted for this work.[57] The reaction concentrations of reagents were 1.4 mM 
dNTPs, 1X Isothermal Amplification Buffer and 10 mM MgSO4 from New England 
Biolabs and 0.4 M betaine from Sigma-Aldrich. The buffer mix was prepared in bulk the 
using above reagents in the aforementioned composition and stored at -20 C between 
experiments. A mastermix was freshly prepared every time for a set of reactions and at this 
point enzymes, DNA intercalating dye and primers were added to the buffer mix. 0.64 
U/μL of Bst 2.0 DNA polymerase, 0.08 U/μL of AMV Reverse Transcriptase (New 
England Biolabs) and 1X EvaGreen (Biotium), a double-stranded DNA intercalating dye, 
were used in reactions.  Bst 2.0 DNA polymerase is an in-silico designed homologue of 
Bst DNA Polymerase and is designed as a robust enzyme with higher thermal stability and 
salt tolerance. The total reaction volume per reaction was 25uL which included 10uL 
purified total RNA sample and 15uL of the mastermix. 
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Primers: 
 Six LAMP primers based on the primer design and testing mentioned above were included 
in the reaction in the following concentrations:  
- 0.2 μM each of F3 (5’-GTC GTG TCA GAC CTT GAA -3’) and B3 (5’-TAG TTC 
CTT TTG GGG CAG-3’) primers,  
- 1.6 μM each of FIP (5’-TCT GGG AAA TGT GTA GCA GGA GGC TGA TGA TGT 
TAA GGG CA 
-3’) and BIP (5’-AAC CCA GTT CCT AAA AAG AAT GTG AGT GGA GGT GGA 
AGA CTG A 
-3’) primers, and  
- 0.8 μM each of LoopF (5’-GGC TTG AAG ACA GTG GTA CAC -3’) and LoopB (5’-
CAG TGA AGA AGA CAG CAG CAA-3’) primers. 
 
 
3.4 On chip reactions 
On-chip detection experiments are divided into 4 steps:  
 
1. Chip preparation and tissue loading,  
 
2. Tissue pixelation,  
 
3. Bulk loading of amplification reagents, and  
 
4. On chip amplification reaction and detection.   
 
Figure 3.6 shows an overview of the process. Each of the above steps are unique and 
required significant innovation in terms of protocol development and characterization, the 
details about which are discussed below: 
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3.4.1 Chip preparation and tissue loading 
The fabricated microwell array chips were degreased (Acetone, Isopropanol, water) and 
piranha cleaned (H2O2:H2SO4 1:1) to remove any organic contaminants prior to use. A 
7um cryosection was made using a Leica cryostat of the prostate cancer xenograft tumor 
tissue (grown in mice using LNCaP cells). The chip was gently placed over the cryosection 
to transfer the tissue on the chip and it was immediately stored at -80C for future use. Care 
must be taken to avoid thawing of the cryosection during this process as it would active the 
RNases and cause RNA degradation. 
 
3.4.2 Tissue pixelation 
Loading of the cryosectioned tumor tissue in the above step gives a 7um thick continuous 
disc of tissue on the microwell array chip. The spatial location of particular well in the 
array will act as relative coordinates for the corresponding location in the tissue. To 
perform a spatial gene expression analysis on chip we need to run independent 
amplification reactions in each well of the array and this would require cutting the 
cryosection into small pixels and placing those tissue pixels into the underlying wells. To 
achieve this sample partitioning we developed a novel technique using 
Polydimethylsiloxane (PDMS). The chip with loaded tissue is taken out of the -80C freezer 
and dried at 60C for 1 minute. Drying reduces the RNase activity and prevents RNA 
degradation. A freshly prepared PDMS is then placed on top of the tissue-chip assembly 
and centrifuged at 1000 rpm for 30 seconds. PDMS is a viscoelastic material and deforms 
when a force is applied to it. During the centrifugation step the PDMS deforms into the 
wells under the centrifugal force and in the process cuts and pushes the overlying tissue 
curtain into the underlying wells. This step, which takes less than a minute in total, 
partitions 1 sample (tissue cryosection disc) into thousands of individual samples (tissue 
pixels in each well). A schematic of the process is shown in the figure 3.7. 
 
3.4.3 Bulk loading of amplification reagents 
The next big challenge after the tissue pixilation is loading the amplification reagents onto 
the chip. There are 2 key challenges to this step:  
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Figure 3.6: Schematic of process overview. 1) Loading of tissue cryosection on chip, 2) Pixelation of tissue 
on chip, 3) Loading of amplification reagents, 4) RT-LAMP reaction on chip   
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Figure 3.7: Cross-sectional schematic of the tissue pixilation process 
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1. Number of wells: There are 5625, 100um wide wells each of 175pL volume, in an 
array spanning roughly 8mmX8mm external dimensions. There are a few 
commercial solutions for spotting arrays of nanodroplets [58], [59]. However, 
spotting picoliter volumes in 1um spacing precisely is a different story all together. 
Moreover, all these commercial tools have large dead volumes (milliliters of 
solution that are used to fill reservoirs but can’t be used for droplets) or the system 
doesn’t allow alignment of the surface. LAMP reagents are expensive and reaction 
volumes don’t exceed 100uL making it unaffordable to loose milliliters in dead 
volume. In addition to the above, loading over 5000 wells using any commercial 
microinjector system would take hours.  
 
2. Edge width between any 2 wells: We needed the edges to be sharp for the tissue 
pixelation step and also to avoid tissue loss over the edge surface and therefore the 
edge widths were fabricated to be close to 1um. Any reagent loading protocol we 
use would have to make sure that there is no cross talk or fluid connection between 
any 2 wells once the fluid loading is complete. 
 
To address the above issues we developed a novel reagent loading technique that allows 
homogenous filling of liquid in each well while preventing cross talk once the reagent 
loading is complete. A fluorescent rhodamine dye in water was used to characterize this 
process. The process started by pipetting 5ul dye on chip after the tissue pixelation step. 
The chip was then dipped in mineral oil, taken out and blown gently with compressed air. 
We find that the excess dye, which is outside of the wells, tends to ball up under the layer 
of oil due to water-oil interactions and gets easily removed from the chip. The wells which 
are hydrophilic (due to the presence of SiO2 and/or Tissue) retain the dye due to the 
capillary forces. Since there is no external force holding the fluid outside of the wells, other 
than the weak Vander Waals forces and hydrogen bonds (cohesive forces) acting between 
the fluid inside and fluid outside the wells, the compressed air easily shears away the excess 
fluid and removes it from the chip. The mineral oil facilitates the above process and also 
acts as an envelope for the finally filled wells that prevents the evaporation of the picoliters 
of volume in each well. This simple yet powerful technique fills thousands of wells 
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homogenously and reproducibly in less than 30 seconds. A schematic of the process is 
shown in figure 3.8.  
 
3.4.4 On chip amplification reaction and real-time detection 
Once the amplification regents are loaded into the wells using the above method, the chip 
is put inside mineral oil in copper bowl and placed on a hot plate at 65 C. The amplification 
reaction on chip was monitored real time by taking fluorescence images every minute and 
recording the fluorescence intensity. NIS-Elements 3.4 (Nikon Instruments Inc. Melville, 
NY) with a FITC filter, automatic shutter, ND back filter at 1 and an analog gain of 8x was 
used for the imaging. The automated shutter avoided any fluorescence dye bleaching. The 
images were saved for future analysis. 
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               Figure 3.8: Cross-sectional schematic of reagent loading mechanism 
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4 Results, discussion and future work: 
 
4.1 Off chip reactions 
RT-LAMP reactions were performed with purified RNA in water from tissue cryosections 
and serial dilutions of this purified total RNA was used for this first experiment. (Figure 
4.1). Threshold count was taken as the time when 20% of the maximum fluorescence 
intensity was reached and the data was visually analyzed for any discrepancy. In the second 
experiment for off-chip reaction characterization, purified total RNA in water from 
cultured LNCaP cells (the same cells were used to grow prostate cancer xenograft in mice) 
was used for serial dilutions experiment and a standard curve drawn (Figure 4.2). The 
purified total RNA was measured using a Nanodrop spectrophotometer for both the 
experiments. Total purified RNA used in the reaction shown as 1x in the figure 4.1 had the 
equivalent total RNA as in a single 7um tissue cryosection and a final RNA concentration 
of 98 ng/ul. In the second experiment (fig 4.2) the reaction showed as 10000 cells had total 
purified RNA equivalent to 10000 cells and a final reaction concentration of 37.6 ng/ul.  
 
In both the above experiments, the standard curves were found to be log linear. We noticed 
a difference in the maximum fluorescence for different dilutions in both the experiments. 
Maximum fluorescence increases with increasing dilution factor. A similar trend was seen 
in our previous work on HIV-1 viral RNA RT-LAMP reactions. Repetitions of the same 
experiments with the same amount of purified total RNA were performed to confirm that 
the difference in maximum fluorescence intensity did not affect the threshold amplification 
times. 
 
For the third off chip experiment, cells were spiked directly in the reaction tubes at known 
amounts using volume based measurements. The results of the experiment are summarized 
in figure 4.3. For all the off-chip reactions, negative controls were run with no RNA in the 
same experimental run.  
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4.2 On chip: Tissue pixelation 
To characterize the tissue pixelation process, rat brain tissue cryosections (7um) were used. 
The samples were fixed and stained using DAPI post pixilation and imaged under 
fluorescence microscope. SEM of the same sample was also performed to visualize the 
tissue in the wells. Figure 4.4 shows the images of the sample after the pixelation process. 
It can be noted that in the fluorescence image the well edges can be seen as dark lines 
indicating that the tissue was pushed inside the wells. The blue dots in the stained sections 
are the nuclei. SEM images of the same sample show tissue at the well bottom. 
 
4.3 On chip: Bulk loading of amplification reagents 
Wells loaded with rhodamine dye in water were imaged using a fluorescence microscope 
and image analysis performed on the images. The edges between any 2 wells can be seen 
as dark lines indicating the absence of any die over the edge, i.e. the edges are not 
submerged in fluid. This would prevent any crosstalk between adjacent wells and 
independent reactions can be performed in each well. The mean fluorescence intensity in 
each well is a function of the volume of dye in the well as shown by the curve in the figure 
4.5. This curve was drawn by injecting known dye volumes in wells using a microinjector 
and then imaging it with Olympus BX51 upright fluorescence microscope using TRITC 
filter at 2 sec exposure and 4X analog gain. The bulk loaded chip, imaged with the same 
settings, was analyzed for mean fluorescence intensity of all the wells and a histogram was 
drawn to visualize the variation in filled well volumes across the chip. Three cases of low, 
mean and high fluorescence intensities of rhodamine dye filled wells are also shown in the 
figure 4.6. The cases of cross-talk between wells were quantified for the whole chip and it 
was found that discrepancies were confined majorly to the chip microwell array edges. 
 
 
4.4 Future work 
All the pre-cursor steps of reaction design and testing, tissue pixelation and reagent loading 
have been characterized and we are currently working on on-chip reaction directly from 
tissue. The results from on-chip amplification will be compared with LCM coupled with 
RT-qPCR technique for confirmation. 
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Figure 4.1: Raw thermocycler fluorescence data (a) and standard curve (b) for purified total RNA 
extracted from tissue. 1x has 98 ng/ul concentration of purified total RNA per reaction.  
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Figure 4.2: Raw thermocycler fluorescence data (a) and standard curve (b) for purified total RNA 
extracted from LNCaP cell. 1x has 37.6 ng/ul concentration of purified total RNA per reaction.  
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Figure 4.3: Raw thermocycler fluorescence data (a) and standard curve (b) for LNCaP cells spiked 
directly in solution. 
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Figure 4.4: SEM image (left) and fluorescence image (right) of the same pixelated sample. The 
fluorescence image was taken after staining the sample with DAPI for visualizing the nucleii. The 
sample was rat brain cryosection 7um thick. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Well fluorescence vs volume calibration done by microinjecting known amounts of 
rhodamine dye in a well followed by image analysis 
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Figure 4.6: characterization of bulk picoliter volume reagent loading technique using rhodamine dye. a) 
Histogram showing distribution of well filling across the chip through mean fluorescence intensity per 
well b) Quantification of cross-talk between wells throughout the chip. Percentage is for number of 
wells for a particular scenario/ total number of wells on chip. 
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